(S)-CFT7455 manufacturers
- CFT7455
-
- $79.00 / 1mg
-
2024-11-19
- CAS:2504235-67-8
- Min. Order:
- Purity: 97.93%
- Supply Ability: 10g
|
| | (S)-CFT7455 Basic information |
| Product Name: | (S)-CFT7455 | | Synonyms: | (S)-CFT7455;CFT7455;(S)-3-(6-(4-(morpholinomethyl)benzyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione;cereblon,CFT 7455,Ligands for E3 Ligase,anti-cancer agent,inhibit,CFT-7455,Inhibitor,CFT7455,orally active,E3 ligase-recruiting Moiety,IKZF3 degrader,IKZF1;Cemsidomide;2,6-Piperidinedione, 3-[6-[[4-(4-morpholinylmethyl)phenyl]methyl]-2-oxobenz[cd]indol-1(2H)-yl]-, (3S)-;(3S)-3-[6-[[4-(4-morpholinylmethyl)phenyl]methyl]-2-oxo-1-benzo[cd]indolyl]piperidine-2,6-dione;(S)-3-(6-(4-(Morpholinomethyl)benzyl)-2-oxobenzo[cd]indol-1(2H)-yl)piperidine-2,6-dione , Cemsidomide | | CAS: | 2504235-67-8 | | MF: | C28H27N3O4 | | MW: | 469.54 | | EINECS: | | | Product Categories: | | | Mol File: | 2504235-67-8.mol |  |
| | (S)-CFT7455 Chemical Properties |
| Boiling point | 738.0±60.0 °C(Predicted) | | density | 1.347±0.06 g/cm3(Predicted) | | pka | 10.70±0.40(Predicted) | | form | Solid | | color | Light yellow to green yellow |
| | (S)-CFT7455 Usage And Synthesis |
| Uses | Cemsidomide (CFT7455) is a ubiquitin ligase pathway Ikaros/Aiolos degrader with molecular glue activity[1]. Cemsidomide has a GI50 of 0.05 nM for NCIH929.1 cells. | | in vivo | In mouse xenograft tumor models, Cemsidomide demonstrates dose dependent efficacy from 3 μg/kg/day to 100 μg/kg/day. In several tumor xenografts tested daily dosing of Cemsidomide at dose of 30 μg/kg/day to 100 μg/kg/day led to durable tumor regression[1].
Cemsidomide (0.1 mg/kg/day; for 21 days) promotes tumor regression in the H929 tumor xenograft model (95% tumor growth inhibition by 7 days)[2]. | | IC 50 | Cereblon: 0.9 nM (Kd) | | References | [1] David Proia, et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1.
[2] James A. Henderson, et al. Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models. Cancer Res (2021) 81 (13_Supplement): LB007. |
| | (S)-CFT7455 Preparation Products And Raw materials |
|